Clinical Trial NCT04449874 demonstrated that the ORR of Divarasib combined with cetuximab (EGFR monoclonal antibody) in colon cancer patients with KRAS G12C mutations reached 62.5%, surpassing the ORRs of other KRAS G12C inhibitors, including sotorasib+panitumumab (26.4%) and adagrasib+cetuximab (46%) reported in previous studies [60,61,62]. Here, KRAS is linked to colonic neoplasm.